Hims & Hers Health (NYSE:HIMS) Price Target Raised to $27.00

Hims & Hers Health (NYSE:HIMS) had its target price lifted by Deutsche Bank Aktiengesellschaft from $23.00 to $27.00 in a research note published on Wednesday,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock.

Other research analysts also recently issued research reports about the stock. Truist Financial boosted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Bank of America raised their price target on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, October 21st. TD Cowen raised their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Eight analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.21.

Hims & Hers Health Trading Down 0.9 %

HIMS traded down $0.21 on Wednesday, hitting $23.41. 17,983,781 shares of the company’s stock were exchanged, compared to its average volume of 13,702,758. The firm has a 50-day moving average price of $18.75 and a 200-day moving average price of $18.41. The stock has a market cap of $5.03 billion, a price-to-earnings ratio of 53.22 and a beta of 1.06. Hims & Hers Health has a fifty-two week low of $6.58 and a fifty-two week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.04) earnings per share. On average, equities analysts predict that Hims & Hers Health will post 0.22 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the transaction, the chief financial officer now directly owns 145,763 shares of the company’s stock, valued at approximately $2,960,446.53. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the transaction, the insider now directly owns 169,935 shares of the company’s stock, valued at $3,935,694.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now directly owns 145,763 shares of the company’s stock, valued at $2,960,446.53. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 854,547 shares of company stock worth $15,987,230. 17.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC boosted its position in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the second quarter valued at approximately $111,000. CWM LLC boosted its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Finally, Amalgamated Bank boosted its position in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.